Biomedical papers, 2012 (vol. 156), issue 2

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2012, 156(2):103-107 | 10.5507/bp.2012.025

Prostate cancer – the role of magnetic resonance imaging

Ingrid Mocikovaa, Jozef Babelab, Vladimir Balazb
a Radiology Department, F.D. Roosevelt Faculty Hospital, nam. gen. Svobodu 1, 97517 Banska Bystrica, Slovak Republic
b Urology Clinic, F.D. Roosevelt Faculty Hospital, nam. gen. Svobodu 1, 97517 Banska Bystrica, Slovak Republic

Background: This article reviews the potential of magnetic resonance imaging (MRI) in prostate cancer diagnosis.

Methods: Systematic scan of Pubmed, Ovid, Medline, Elsevier search engines was used, additional information was found through bibliographic review of relevant articles.

Results: Substantial progress has been made in the imaging of prostate cancer in MR imaging, as well as in advanced MR spectroscopy.

Conclusions: MRI is a non-invasive and direct imaging modality useful for cancer staging, therapy response, detection of recurrence and guided biopsy in previous negative biopsies. MRI with 3.0T system, whole-body MRI, dynamic contrast enhanced MRI, diffusion-weighted imaging (DWI) and MR spectroscopy (MRS) have improved tumor staging, assessment of tumor volume, aggressiveness or recurrence. Implementation of endorectal/phased array superficial MRI findings on 1.5 or 3.0T systems into nomograms for prostate pretreatment prediction is warranted. Surface phasedarray coil MRI accurately defines prostate cancer with elevated risk of extraprostatic disease.

Keywords: magnetic resonance imaging, prostate cancer, advanced MRI

Received: August 22, 2011; Accepted: February 21, 2012; Published: May 10, 2012; Published: June 1, 2012


References

  1. Hricak H, Choyk PL, Eberhardt S, Leibel SA,Scardino PT. Imaging prostate cancer: a multidisciplinary perspective. Radiology 2007;243:28- 53. Go to original source... Go to PubMed...
  2. Wang L. Incremental value of magnetic resonance imaging in the advanced management of prostate cancer. World J Radiol 2009;31:3- 14. Go to original source... Go to PubMed...
  3. Kattan MW, Scardino PT. Prediction of progression: nomograms of clinical utility. Clin Prostate Cancer 2002;1:90-6. Go to original source... Go to PubMed...
  4. Claus FG, Hricak H, Hattery RR. Pretreatment evaluation of prostate cancer: role of MR imaging and 1 H MR spectroscopy. Radiographics 2004;24:Suppl1:16780. Go to original source... Go to PubMed...
  5. Giusti S, Caramella D, Fruzzetti E, Lazzereschi M, Tognetti A, Bartolozzi C. Peripheral zone prostate cancer. Pre-treatment evaluation with MRI and 3D (1)H MR spectroscopy imaging: correlation with pathologic findings. Abdom Imaging 2010; 35:757-63. Go to original source... Go to PubMed...
  6. Wang L, Van den Bos IC, Hussain SM, Pattynama PM, Vogel MW, Krestin GP. Post-processing of dynamic gadolinium-enhanced magnetic resonance imaging exams of the liver:explanation and potential clinical applications for colour-coded qualitative and quantitative analysis. Acta Radiol 2008;49:6-18. Go to original source... Go to PubMed...
  7. Wang L, Mullerad M, Chen HN, Eberhardt SC, Kattan MW, Scardino PT, Hricak H. Prostate cancer: incremental value of endorectal MR findings for prediction of extracapsular extension. Radiology 2004;232:133-9. Go to original source... Go to PubMed...
  8. Futterer JJ, Engelbrecht RM, Jafer JG,Hartman RP, King BF, Hulsbergen-Van de Kaa CA, Witjes JA,Barentsz JO. Prostate cancer: comparison of local staging accuracy of pelvic phased - array coil versus integrated endorectal-pelvic phased-array coils. Eur Radiol 2007;17:1055-65. Go to original source... Go to PubMed...
  9. Park BK, Kim B, KimCK, Lee HM, Kwon GY. Comparison of Phasedarray 3.0T and endorectal 1.5T magnetic resonance imaging in the evaluation of local staging accuracy for prostate cancer. Comput Assist Tomogr 2007;31(4):534-8. Go to original source... Go to PubMed...
  10. Kim B, Breau RH, Papadatos D, Fergusson D, Doucette S, Cagiannos I, Morash C. Diagnostic accuracy of surface coil magnetic resonance imaging at 1.5T for local staging of elevated risk prostate cancer. Can Urol Assoc J 2010;4:257-62. Go to original source... Go to PubMed...
  11. Augustin H, Fritz GA, Ehammer T, Auprich M,Pummer K. Accuracy of 3-Tesla magnetic resonance imaging for the staging of prostate cancer in comparison to the Partin tables. Acta Radiol 2009;50:562-9. Go to original source... Go to PubMed...
  12. Verma S, Rajesh A, Morales H, Lemen L,Bills G,Delworth M, Gaitonde K,Yinq J,Samartunga R, Lamba M. Assessment of aggressiveness of prostate cancer: correlation of apparent diffusion coefficient with histologic grade after radical prostatectomy. AJR Am J Roentgenol 2011;196:374-81. Go to original source... Go to PubMed...
  13. Iwazawa J, Mitani T, Sassa S, Shoichi O. Prostate cancer detection with MRI:is dynamic contrast-enhanced imaging necessary in addition to diffusion-weighted imaging? Diagn Interv Radiol. DOI 10.4261/1305-3825.DIR3605-10.1. Go to original source...
  14. Panebianco V, Sciarra A, Lisi D, Galati F, Buoconore V, Catalano C, Gentile V, Laghi A, Passariello R. Prostate cancer:1HMRS-DCEMR at 3T versus [(18)] choline PET/CT in the detection of local prostate cancer recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP). Eur J Radiol Feb 2011 [Epub ahead of print] http://dx.doi.org/10.1016/j.ejrad.2011.01.095. Go to original source... Go to PubMed...
  15. Mazaheri Y, Hricak H, Fine SW, Akin O, Shukla-Dave A, Ishill NM, Moskowitz CS,Grater JE,Reuter VE, Zakian KL, Touijer KA, Koutcher JA. Prostate tumor volume measurement with combined T2- weighted imaging and diffusion-weighted MR: correlation with pathologic tumor volume. Radiology 2009;25:449-57. DOI:10.1148/ radiol.2523081423. Go to original source... Go to PubMed...
  16. Nakashima J,Tanimoto A, Imai Y, Mukai M, Horiguchi Y, Nakagawa K, Oya H, Ohigashi T, Marumo K, Murai M. Endorectal MRI for prediction of tumor site, tumor size, and local extension of prostate cancer. Urology 2004;64:101-5. DOI:10.1016/j.urology.2004.02.036. Go to original source... Go to PubMed...
  17. Lawrentschuk N, Lindner U. Recent advances in magnetic resonance imaging of prostate cancer. F1000 Med Rep 2010;2:86. DOI:10.3410/ M2-86. Go to PubMed...
  18. Chopra R, Tang K, Butnyk M, Boyes A, Sugar L, Appu S, Klotz L, Bronskill M. Analysis of the spatial and temporal accuracy of heating in the prostate gland using transurethral ultrasound therapy and active MR temperature feedback. Phys Med Biol 2009;54:2615-33. DOI:10.1088/0031-9155/54/9/002. Go to original source... Go to PubMed...
  19. Rouvierer O, Girouin N, Glas L, Ben Cheikh A, Gelet A, Mége - Lechevallier F, Rabilloud M, Chapelon JY, Lyonnet D. Prostate cancer transrectal HIFU ablation: detection of local recurrences using T2-weighted and dynamic contrast-enhanced MRI. Eur Radiol 2010;20:48-55. DOI 10.1007/s00330-009-1520-5. Go to original source... Go to PubMed...
  20. Harisinghani MG, Barentz JO, Hahn PF, Deserno WM, Tabataei S, van de KAA CH, de la Rossete J, Weissleder R. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003;348:2491-9. Go to original source... Go to PubMed...
  21. Naughton CK, Ornstein DK, Smith DS, Catalona WJ. Pain and morbidity of transrectal ultrasound guided prostate biopsy: a prospective randomized trial of 6 versus 12 cores. J Urol 2000;163:168-71. Go to original source... Go to PubMed...
  22. Cheikh AB, Girouin N, Colombel M, Maréchal JM, Gelet A, Bissery A, Rabilloud M, Lyonnet D, Rouviére O. Evaluation of T2-weighted and dynamic contrast- enhanced MRI in localizing prostate cancer before repeat biopsy. Eur Radiol 2009;19:770-8. DOI: 10.1007/s00330-008- 1190-8. Go to original source... Go to PubMed...